These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 8495805)

  • 1. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
    Engerman RL; Kern TS
    Diabetes; 1993 Jun; 42(6):820-5. PubMed ID: 8495805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinal polyol and myo-inositol in galactosemic dogs given an aldose-reductase inhibitor.
    Kern TS; Engerman RL
    Invest Ophthalmol Vis Sci; 1991 Dec; 32(13):3175-7. PubMed ID: 1748548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capillary basement membrane in retina, kidney, and muscle of diabetic dogs and galactosemic dogs and its response to 5 years aldose reductase inhibition.
    Engerman RL; Kern TS; Garment MB
    J Diabetes Complications; 1993; 7(4):241-5. PubMed ID: 8219367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldose reductase and the development of renal disease in diabetic dogs.
    Kern TS; Engerman RL
    J Diabetes Complications; 1999; 13(1):10-6. PubMed ID: 10232704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galactose-induced retinal microangiopathy in rats.
    Kern TS; Engerman RL
    Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):490-6. PubMed ID: 7843917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The polyol pathway in retinal microangiopathy.
    Robison WG; Kinoshita JH; Kador PF
    Drugs; 1986; 32 Suppl 2():19-22. PubMed ID: 3098542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs.
    Engerman RL; Kern TS; Larson ME
    Diabetologia; 1994 Feb; 37(2):141-4. PubMed ID: 8163047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of aldose reductase inhibition on nerve sorbitol and myoinositol concentrations in diabetic and galactosemic rats.
    Yue DK; Hanwell MA; Satchell PM; Handelsman DJ; Turtle JR
    Metabolism; 1984 Dec; 33(12):1119-22. PubMed ID: 6438438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperglycemia as a cause of diabetic retinopathy.
    Engerman RL; Kern TS
    Metabolism; 1986 Apr; 35(4 Suppl 1):20-3. PubMed ID: 3083205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldose reductase activity and basement membrane thickening.
    Frank RN
    Metabolism; 1986 Apr; 35(4 Suppl 1):35-40. PubMed ID: 3083207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening--prevention by an aldose reductase inhibitor.
    Das A; Frank RN; Zhang NL; Samadani E
    Exp Eye Res; 1990 Mar; 50(3):269-80. PubMed ID: 2108050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats.
    Tilton RG; Pugliese G; LaRose LS; Faller AM; Chang K; Province MA; Williamson JR
    J Diabet Complications; 1991; 5(4):230-7. PubMed ID: 1779018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil.
    Beyer-Mears A; Ku L; Cohen MP
    Diabetes; 1984 Jun; 33(6):604-7. PubMed ID: 6427041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldose reductase inhibition and retinopathy.
    Robison WG
    Diabetes; 1994 Feb; 43(2):337-9. PubMed ID: 8288059
    [No Abstract]   [Full Text] [Related]  

  • 15. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor.
    Robison WG; Kador PF; Kinoshita JH
    Science; 1983 Sep; 221(4616):1177-9. PubMed ID: 6612330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrastructural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats.
    Vinores SA; McGehee R; Lee A; Gadegbeku C; Campochiaro PA
    J Histochem Cytochem; 1990 Sep; 38(9):1341-52. PubMed ID: 2117624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention or moderation of some ultrastructural changes in the RPE and retina of galactosemic rats by aldose reductase inhibition.
    Vinores SA; Campochiaro PA
    Exp Eye Res; 1989 Sep; 49(3):495-510. PubMed ID: 2507341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs.
    Datiles MB; Kador PF; Kashima K; Kinoshita JH; Sinha A
    Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2201-4. PubMed ID: 2122961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldose reductase inhibitors and late complications of diabetes.
    Benfield P
    Drugs; 1986; 32 Suppl 2():43-55. PubMed ID: 3098544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of polyol pathway activity in diabetic and galactosemic rats by the aldose reductase inhibitor CP-45,634.
    Peterson MJ; Sarges R; Aldinger CE; MacDonald DP
    Adv Exp Med Biol; 1979; 119():347-56. PubMed ID: 115231
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.